Adial Pharmaceuticals announced on February 12, 2025, that the United States Patent and Trademark Office issued patent number 12,221,654 on February 11, 2025. This patent expands the covered methods of identifying patients with specific genetic markers linked to substance use disorders.
The treatment approach involves detecting the TT genotype of rs1042173 in the serotonin transporter gene (SLC6A4) and administering AD04, the company’s investigational new drug product. These methods are tailored for individuals suffering from conditions such as opioid dependence, opioid abuse, and alcohol dependence.
This patent is an important milestone for Adial as it positions AD04 to treat opioid use disorder and other drug dependencies, in addition to its initial indication of alcohol use disorder. The combination of genetic diagnostics with precision medicine aims to improve outcomes for patients who may not respond to traditional treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.